证券代码：002099 证券简称：海翔药业 公告编号：2025-057 浙江海翔药业股份有限公司 关于与国科大杭州高等研究院签署共建先进合成技术产业 研究院合作协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、协议签署概况 2025 年 12 月 8 日，浙江海翔药业股份有限公司（以下简称"公司"）与国 科大杭州高等研究院（以下简称"杭高院"）签署了《共建先进合成技术产业研 究院合作协议》（以下简称"《研究院合作协议》"），双方本着"优势互补、 市场主导、开放公平、互惠共赢"的原则，充分利用校企双方的人才优势、技术 优势、资源优势，共同组建先进合成技术产业研究院。产业研究院的研发方向主 要聚焦医药原料药、中间体、染料、新材料的开发与工业化等，合作总金额 5,000 万元人民币。 本协议签署不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。根据《深圳证券交易所股票上市规则》等法律法规、规范 性文件及《公司章程》等有关规定，本事项无须提交公司董事会或股东会审议。 二、合作方的基本情况 1、名称：国科大杭州高等研究院 3、开 ...

Group 1 - The company, Haishang Pharmaceutical (002099.SZ), has signed a cooperation agreement with the Hangzhou Advanced Research Institute of the University of Science and Technology of China to establish a joint advanced synthetic technology industrial research institute [1] - The research focus of the industrial research institute will primarily be on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials [1] - The total investment for this collaboration amounts to 50 million yuan [1]

Group 1 - The core viewpoint of the article is that Haishang Pharmaceutical (002099) has signed a cooperation agreement with the Hangzhou Advanced Research Institute of the University of Science and Technology of China to establish an Advanced Synthesis Technology Industry Research Institute, with a total investment of 50 million yuan [1] - The research focus of the new institute will be on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials [1] - The research team led by Zhang Xiaoheng at the Hangzhou Institute has proposed a new method for the direct deamination of aromatic amines, which is safe and economical, potentially revolutionizing traditional high-risk processes in various fields such as pharmaceuticals, dyes, and materials manufacturing [1]

Group 1 - The core point of the article is that Haishang Pharmaceutical has signed a cooperation agreement with the Hangzhou Advanced Research Institute of the University of Science and Technology of China to establish a joint advanced synthesis technology industrial research institute [1] - The research focus of the industrial research institute will primarily be on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials [1] - The total investment for this collaboration amounts to 50 million yuan [1]

证券日报网讯 12月8日，海翔药业在互动平台回答投资者提问时表示，公司目前生产基地主要分布在台 州地区，当前生产经营活动正常有序，在手订单储备与客户需求节奏相匹配，产能利用率维持在合理水 平。 （编辑 丛可心 王雪儿） ...

证券日报网讯12月1日，海翔药业（002099）在互动平台回答投资者提问时表示，截至11月28日公司股 东人数为27406户。 ...

证券代码：002099 证券简称：海翔药业 公告编号：2025-056 浙江海翔药业股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三 ...

Company Overview - Zhejiang Haixiang Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang Province, established on May 7, 1998, and listed on December 26, 2006 [1] - The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of the company includes: 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization, 1.02% from other sources, and 0.49% from formulations [1] Stock Performance - On November 21, Haixiang Pharmaceutical's stock fell by 5.03%, trading at 5.85 yuan per share, with a transaction volume of 88.72 million yuan and a turnover rate of 0.92%, resulting in a total market capitalization of 9.469 billion yuan [1] Shareholder Information - Among the top ten circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF today is approximately 3.2111 million yuan [2] Fund Management - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 16 days. The total asset size of the fund is 122.76 billion yuan [3] - During Cui Lei's tenure, the best fund return was 180.57%, while the worst return was -15.93% [3]

证券日报网讯 11月18日晚间，海翔药业发布公告称，同意选举陈敏杰先生为公司第八届董事会职工代 表董事。 （文章来源：证券日报） ...

Core Points - The company announced the extension of its 2020 employee stock ownership plan by 12 months, now set to expire on November 19, 2026 [1] Summary by Category - **Company Announcement** - The company will hold its eighth board meeting on November 18, 2025, to review the proposal for the extension of the employee stock ownership plan [1]